These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 4509041)

  • 21. Synergistic cooperation between isoantiserum and immune lymphoid cells: in vitro studies with a syngeneic rat lymphoma.
    Ortiz de Landazuri M; Kedar E; Fahey JL
    J Immunol; 1974 Jun; 112(6):2102-10. PubMed ID: 4825787
    [No Abstract]   [Full Text] [Related]  

  • 22. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
    Cruse JM; Whitten HD; Lewis GK; Watson ES
    Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
    [No Abstract]   [Full Text] [Related]  

  • 23. Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase.
    Hughes RC; Palmer PD; Sanford BH
    J Immunol; 1973 Oct; 111(4):1071-80. PubMed ID: 4728677
    [No Abstract]   [Full Text] [Related]  

  • 24. Connection between the anti-organ and anti-nuclear titres of antilymphocyte sera and their inhibitory effect on skin graft rejection in mice.
    Fekete B; Petrányi G; Szegedi G; Szabó G
    Haematologia (Budap); 1971; 5(4):419-23. PubMed ID: 4948255
    [No Abstract]   [Full Text] [Related]  

  • 25. The mechanism of immunological enhancement of H-2-incompatible skin grafts in mice.
    Chutná J
    Transplantation; 1971 Jul; 12(1):28-35. PubMed ID: 4932695
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunoglobulin biosynthesis by normal and leukemic human peripheral blood lymphocytes.
    Nies KM; Oberlin MA; Brown JC; Halpern MS
    J Immunol; 1973 Oct; 111(4):1236-42. PubMed ID: 4580668
    [No Abstract]   [Full Text] [Related]  

  • 27. The cytotoxic reactivity and sialic acid content of human lymphoid cells.
    Reisner EG; Flye MW; Chung KS; Amos DB
    Tissue Antigens; 1974; 4(1):7-20. PubMed ID: 4545917
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity.
    Kedar E; Otiz de Landazuri M; Fahey JL
    J Immunol; 1974 Jan; 112(1):26-36. PubMed ID: 4812174
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of enzymatic removal of cell surface sialic acid on the adherence of Walker 256 tumor cells to mesothelial membrane.
    Cormack D
    Cancer Res; 1970 May; 30(5):1459-66. PubMed ID: 5426949
    [No Abstract]   [Full Text] [Related]  

  • 30. Humoral antibodies in the host directed against tumor cells after suppression of ascites tumor by heteroimmune sera.
    Rao VS; Sirsi M
    Cancer Res; 1971 Aug; 31(8):1153-8. PubMed ID: 5095980
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in cell surface properties during the in vivo growth of Moloney lymphoma.
    Fenyö EM; Peebles PT; Wahlström A; Klein E; Cochran AJ
    Isr J Med Sci; 1973 Mar; 9(3):239-50. PubMed ID: 4575651
    [No Abstract]   [Full Text] [Related]  

  • 32. Modulation of the immune response to transplantation antigens. I. The effects of immunization using adjuvants on the immune response of mice to a tumour allograft.
    Zola H
    Clin Exp Immunol; 1972 Aug; 11(4):585-93. PubMed ID: 4563711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The serologic behaviour of neuraminidase-treated lymphoid cells. Alloantigenicity and complement sensitivity.
    Ray PK; Gewurz H; Simmons RL
    Clin Exp Immunol; 1972 Jul; 11(3):441-60. PubMed ID: 5042921
    [No Abstract]   [Full Text] [Related]  

  • 34. "Unmasking" of human lymphoid cell heteroantigens by neuraminidase treatment.
    Rosenberg SA; Plocinik BA; Rogentine GN
    J Natl Cancer Inst; 1972 May; 48(5):1271-6. PubMed ID: 4624148
    [No Abstract]   [Full Text] [Related]  

  • 35. Alteration of the specificity of antitumor antisera by the use of passively administered antibody.
    Ungaro PC; Drake WP; Buchholz DH; Mardiney MR
    Cancer Res; 1972 Jul; 32(7):1521-5. PubMed ID: 5030580
    [No Abstract]   [Full Text] [Related]  

  • 36. Exposure by desialylation of myeloid antigens on acute lymphoblastic leukemia cells.
    Stockinger H; Majdic O; Liszka K; Aberer W; Bettelheim P; Lutz D; Knapp W
    J Natl Cancer Inst; 1984 Jul; 73(1):7-11. PubMed ID: 6204096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of Gross leukemia cell-surface antigens: a kind of antigenic modulation.
    Aoki T; Johnson PA
    J Natl Cancer Inst; 1972 Jul; 49(1):183-92. PubMed ID: 5037434
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of some cell surface modifications on the cytotoxic effect of immune lymphocytes in vitro].
    Brondz BD; Shamborant OG
    Tsitologiia; 1972 Feb; 14(2):189-96. PubMed ID: 5062397
    [No Abstract]   [Full Text] [Related]  

  • 39. Classification of human leukemia by membrane antigen analysis with xenoantisera.
    Metzgar RS; Dowell BL; Lachman LB; Jones NH; George FW
    Cancer Res; 1981 Nov; 41(11 Pt 2):4781-85. PubMed ID: 6794906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro cytotoxicity of normal serum factor(s) on neuraminidase-treated Ehrlich ascites tumor cells and murine leukemia L 1210 cells.
    Sethi KK; Brandis H
    Z Immunitatsforsch Exp Klin Immunol; 1972 May; 143(4):426-9. PubMed ID: 4282925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.